This antagonistic effect of IL-38 thereby restricts anti-tumor immunity by inhibition of pro-inflammatory cytokine release of macrophages [51] and TH17 response of tumor-infiltrating γδ T cells [52]. This evidence concerns the gene IL1F10 and neoplasm.